KPV Tripeptide Sourcing Vocabulary and NF-κB Inhibition Pharmacology: A Research Review of Alpha-MSH C-Terminal Fragment PepT1 Uptake, Antimicrobial Properties and Catalogue Query Resolution

By Peptide Insider Research Desk · October 11, 2026 · Research-Use Only

The tripeptide KPV (Lys-Pro-Val) — catalogued under search strings such as kpv for sale, kpv peptide what is it, kpv 10 peptide, what is kpv used for and kpv peptide where to buy — represents the C-terminal fragment (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH). Unlike full-length α-MSH, KPV does not activate melanocortin receptors at physiologically significant potency and instead exerts anti-inflammatory effects through a receptor-independent mechanism centred on nuclear factor kappa-B (NF-κB) suppression [1, 2]. This review consolidates the peer-reviewed preclinical evidence base for KPV, examines its PepT1-mediated intestinal uptake pathway, and maps the sourcing vocabulary that appears in catalogue searches. All data cited below derive strictly from published research; this article is intended for research reference and is not intended for human or veterinary use.

Key Facts at a Glance

• KPV is a three-amino-acid fragment of α-MSH that suppresses NF-κB nuclear translocation by competing with importin-α3 for the p65/RelA nuclear localisation signal, thereby reducing TNF-α, IL-1β, IL-6 and IL-8 transcription in preclinical cell models [1, 2].
• The peptide is transported across intestinal epithelium via PepT1 (SLC15A1), a proton-coupled di/tripeptide transporter whose expression is upregulated in inflamed colonic tissue, providing a site-selective uptake mechanism observed in DSS-colitis rodent models [3, 4].
• In a 2017 nanoparticle delivery study, hyaluronic acid–functionalised KPV nanoparticles reduced colonic myeloperoxidase activity and disease activity index in mice at concentrations lower than free peptide, suggesting formulation-dependent bioavailability enhancement [5].
• KPV demonstrates direct antimicrobial membrane disruption against Staphylococcus aureus and Candida albicans without impairing host neutrophil function, as reported in cationic peptide interaction studies [6].
• A 2026 cell-based study found that KPV attenuated adipogenesis and lipid accumulation through modulation of ROS-mediated AKT/mTORC1/PPARγ signalling in 3T3-L1 preadipocytes, expanding the investigated signal space beyond classical NF-κB pathways [7].

Molecular Identity and Relationship to α-MSH

α-Melanocyte-stimulating hormone is a tridecapeptide cleaved from pro-opiomelanocortin (POMC) that signals through five G-protein–coupled melanocortin receptors (MC1R–MC5R). Early structure–activity dissection by Getting et al. (2003) established that the C-terminal tripeptide KPV retains anti-inflammatory activity while lacking the His-Phe-Arg-Trp core pharmacophore required for high-affinity MC1R binding [2]. This separation of anti-inflammatory potency from melanogenic signalling is the pharmacological rationale for investigating KPV as an independent research tool compound. The molecular weight of 342.44 Da places KPV well below the conventional peptide size threshold, contributing to its unusual oral absorptive properties discussed below.

Mechanism of Action: NF-κB p65 Nuclear Translocation Block

The canonical anti-inflammatory mechanism attributed to KPV in the published literature involves suppression of NF-κB signalling through at least two convergent routes:

1. Importin-α3 competition. Bhatt and colleagues reported that KPV can enter cells and compete with importin-α3 for the nuclear localisation signal on the p65/RelA subunit, physically preventing nuclear import of the NF-κB heterodimer. Without nuclear translocation, transcription of pro-inflammatory genes (TNF-α, IL-1β, IL-6, IL-8, iNOS) is suppressed [1].

2. IκBα stabilisation. In parallel, KPV has been shown to prevent the phosphorylation-dependent degradation of IκBα, the cytoplasmic inhibitor that sequesters NF-κB in its inactive state. By preserving IκBα, KPV maintains the sequestered p65/p50 complex in the cytoplasm [1, 8].

Crucially, these effects occur without measurable elevation of intracellular cAMP and are preserved in MC1R-deficient cell lines, confirming receptor independence [2, 9]. Ichiyama et al. (1999) demonstrated that systemically administered α-MSH peptides, including KPV-containing fragments, inhibited NF-κB activation in experimental brain inflammation models, broadening the tissue scope beyond peripheral immune cells [9].

PepT1-Mediated Intestinal Uptake

A distinguishing feature of KPV relative to most therapeutic peptides is its compatibility with the proton-coupled oligopeptide transporter PepT1 (gene symbol SLC15A1). Dalmasso et al. (2008) demonstrated in Gastroenterology that KPV is actively taken up by intestinal epithelial cells through PepT1, and that PepT1 expression is upregulated in inflamed colonic mucosa [3]. This creates a site-selective uptake gradient: inflamed tissue absorbs more KPV than healthy tissue, a property that has attracted interest for targeted oral delivery strategies.

Subsequent work by Viennois et al. (2016) showed that PepT1-mediated KPV uptake played a role in a colitis-associated cancer prevention model, where the tripeptide reduced tumour burden in azoxymethane/DSS-treated mice [4]. The PepT1 uptake mechanism is also the basis for nanoparticle delivery platforms that encapsulate KPV for controlled colonic release [5, 10].

Preclinical Evidence Table

Antimicrobial Properties

KPV also belongs to the antimicrobial neuropeptide class. The cationic lysine residue at position 1 facilitates electrostatic interaction with negatively charged bacterial membranes. Patel et al. (2025) characterised the lipopolysaccharide-binding mechanism of α-MSH–derived cationic peptides including KPV against Escherichia coli, demonstrating dose-dependent antibiofilm effects [6]. Li and Chen (2024–2025) placed KPV within the broader antimicrobial neuropeptide family [11, 14]. KPV's antimicrobial action does not appear to suppress host neutrophil bactericidal capacity.

Nanoparticle and Formulation Research

KPV's small size and PepT1 compatibility have spurred formulation research. Xiao et al. (2017) demonstrated that hyaluronic acid–functionalised nanoparticles loaded with KPV showed superior colonic adhesion and efficacy compared with free peptide in DSS-colitis mice [5]. Sun et al. (2021) developed a γ-polyglutamic acid hydrogel that stabilised KPV for TNBS-colitis treatment [10]. Marotti et al. (2024) reported a combined mucosal healing and immunomodulation nanoparticle platform for IBD models [15]. All formulations remain at the preclinical stage.

KPV in the KLOW Blend Context

In the research-peptide catalogue landscape, KPV frequently appears as one of four components in the KLOW blend — alongside BPC-157, TB-500 and GHK-Cu. Queries such as kpv., kpv 10 peptide and what is kpv used for often co-occur with KLOW searches. Within KLOW, KPV contributes the NF-κB–inhibitory axis, BPC-157 provides NO/prostaglandin cytoprotection, TB-500 acts through actin-sequestration, and GHK-Cu operates via copper-dependent MMP/TIMP remodelling. No peer-reviewed study has evaluated the four-component KLOW combination; each component's evidence base remains independent.

Sourcing Vocabulary Crosswalk

Where to Source KPV for Research

Investigators sourcing KPV for preclinical study should verify certificate-of-analysis (CoA) documentation confirming peptide purity (≥ 95 % by HPLC), correct MW by mass spectrometry, and endotoxin content below assay-specific thresholds. Research-grade KPV is available from suppliers including Short Chain Aminos (primary catalogue listing), BioPep, Catalyst Research and Apex Research Services. No vendor has been assessed or endorsed by this publication; researchers should independently verify supplier credentials and lot-specific analytical documentation before procurement.

Frequently Asked Questions

What is KPV peptide and what is it used for?

KPV is a three-amino-acid peptide (Lys-Pro-Val, MW 342.44 Da) derived from the C-terminus of alpha-melanocyte-stimulating hormone. In preclinical research, it is studied for its NF-κB–suppressive and antimicrobial properties. What is kpv used for? It is used strictly as a research tool compound for investigating inflammatory signalling pathways; it is not approved for human or veterinary use [1, 2].

Is KPV peptide available for purchase — where to buy KPV peptide?

Research-grade KPV is available from peptide catalogue suppliers. Queries such as kpv for sale, kpv peptide where to buy and where to buy kpv peptide commonly appear in catalogue search logs. Researchers should verify supplier CoA documentation for purity, identity and sterility before use in any experimental protocol. KPV is sold exclusively for research-use applications.

What does KPV 10 peptide mean in catalogue listings?

The query kpv 10 peptide typically refers to a 10 mg lyophilised vial of KPV tripeptide, a standard catalogue fill size. The numeral denotes mass content, not concentration or activity units.

How does KPV differ from full-length α-MSH?

Full-length α-MSH (13 residues) binds melanocortin receptors (MC1R–MC5R) and induces melanogenesis, cAMP elevation and appetite modulation. KPV (3 residues) lacks the His-Phe-Arg-Trp pharmacophore and does not significantly activate MCRs, instead operating through direct intracellular NF-κB inhibition [2, 9].

Works Cited

1. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. PMID: 18612139
2. Getting SJ, Christian HC, Flower RJ, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. PMID: 12750433
3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177
4. Viennois E, Ingersoll SA, Bhatt AP, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. PMID: 27458604
5. Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. PMID: 28143741
6. Patel P, et al. Antimicrobial and antibiofilm potential of α-MSH derived cationic and hydrophobic peptides against Escherichia coli. Biochim Biophys Acta Biomembr. 2025;1867(1):184394. PMID: 39515599
7. An SH, et al. KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling. Tissue Cell. 2026;93:102686. PMID: 42585803
8. Kannengiesser K, Maaser C, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 18092346
9. Ichiyama T, Sakai T, Catania A, Barsh GS, Furukawa S, Lipton JM. Systemically administered alpha-melanocyte-stimulating peptides inhibit NF-kappaB activation in experimental brain inflammation. Brain Res. 1999;836(1-2):31-37. PMID: 10415402
10. Sun J, et al. Self-cross-linked hydrogel of cysteamine-grafted γ-polyglutamic acid stabilized tripeptide KPV for alleviating TNBS-induced ulcerative colitis in rats. ACS Biomater Sci Eng. 2021;7(10):4859-4869. PMID: 34547895
11. Li X, et al. Antimicrobial neuropeptides and their therapeutic potential in vertebrate brain infectious disease. Front Immunol. 2024;15:1496553. PMID: 39620214
12. Lee JY, et al. Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Cytotechnology. 2026;78:42. PMID: 42064835
13. Bai JS, et al. Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages. Tissue Cell. 2026;94:102752. PMID: 42854645
14. Chen K, et al. Antimicrobial neuropeptides and their receptors: immunoregulator and therapeutic targets for immune disorders. Molecules. 2025;30(3):527. PMID: 39942672
15. Marotti V, et al. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioact Mater. 2024;33:236-252. PMID: 37859689

Disclaimer: This article is provided strictly for research reference. KPV is a research-use-only compound with no regulatory approval for human or veterinary therapeutic application. No content herein constitutes medical advice, dosing guidance, or encouragement of self-administration. Researchers should consult institutional review protocols and applicable regulations before initiating any experimental work.